Skip to main navigation
Skip to search
Skip to main content
Augusta University Research Profiles Home
Help & FAQ
Link opens in a new tab
Search content at Augusta University Research Profiles
Home
Profiles
Research Units
Scholarly Output
Projects
Datasets
Equipment
Activities
Press/Media
Prizes
Third-Generation Tyrosine Kinase Inhibitors and Beyond
Alfonso Quintás-Cardama
, Hagop Kantarjian
,
Jorge Cortes
Research output
:
Contribution to journal
›
Article
›
peer-review
21
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Third-Generation Tyrosine Kinase Inhibitors and Beyond'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Clinical Trials
100%
Bone Marrow
100%
Therapeutic Approaches
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Adenosine Triphosphate
100%
Clinical Activity
100%
Patient's Will
100%
Patient Management
100%
Third Generation
100%
Dasatinib
100%
Investigational Agents
100%
Chronic Myeloid Leukemia
100%
Imatinib
100%
Nilotinib
100%
Second-generation Tyrosine Kinase Inhibitors
100%
Complete Cytogenetic Response
100%
Philadelphia Chromosome
100%
Frontline Therapy
100%
Imatinib Therapy
100%
Sequential Therapy
100%
Third-generation Tyrosine Kinase Inhibitor
100%
T315I mutation
100%
ABL1 mutation
100%
Biochemistry, Genetics and Molecular Biology
Tyrosine Kinase Inhibitor
100%
Imatinib
100%
Adenosine Triphosphate
50%
Cytogenetics
50%
Clinical Trial
50%
Metaphase
50%
Myeloid
50%
Dasatinib
50%
Allogeneic Stem Cell Transplantation
50%
Nilotinib
50%
Philadelphia Chromosome
50%
Medicine and Dentistry
Tyrosine-Kinase Inhibitor
100%
Imatinib
100%
Clinical Trial
50%
Metaphase
50%
Adenosine Triphosphate
50%
Allogeneic Stem Cell Transplantation
50%
Dasatinib
50%
Chronic Myelogenous Leukemia
50%
Philadelphia 1 Chromosome
50%
Nilotinib
50%
Pharmacology, Toxicology and Pharmaceutical Science
Protein Tyrosine Kinase Inhibitor
100%
Imatinib
100%
Clinical Trial
50%
Adenosine Triphosphate
50%
Dasatinib
50%
Philadelphia 1 Chromosome
50%
Chronic Myeloid Leukemia
50%
Nilotinib
50%